Statement of Principles concerning restless legs syndrome (Balance of Probabilities) (No. 114 of 2022)

The central legal mechanism in this instrument is the Statement of Principles model used in veterans’ compensation legislation. The RMA issues SOPs under statutory power to identify, from medical and scientific evidence, the linkages that are sufficient, on the balance of probabilities, to connect a particular kind of injury or disease to relevant service. The SOP operates as an evidentiary rule within the VEA/MRCA claim process (see s 3; s 5).

Key concepts established by the instrument include:

• Restless legs syndrome as a specified clinical entity: s 7(2) sets out the sensorimotor neurological disorder definition with four core clinical features (strong urge to move legs with unpleasant sensations; worse at rest; relieved by movement; worse in evening/night), plus minimum frequency (at least three times per week) and duration (at least three consecutive months), and a requirement that symptoms cause significant distress or impairment and are not solely accounted for by another condition. The instrument explicitly notes mimic conditions such as myalgia, venous stasis and leg cramps.
• Onset versus worsening: the SOP differentiates factors that may be present at the time of clinical onset of RLS (s 9(1)-(9)) from those that may be present at the time of clinical worsening (s 9(10)-(22)). Section 10(2) limits several factors to material contribution to or aggravation of pre‑existing RLS, when the disease was suffered or contracted before or during relevant service but did not arise out of that service.
• Quantified biomedical thresholds: Schedule 1 supplies objective thresholds (for example ferritin <30 micrograms per litre for iron deficiency; GFR <15 mL/min/1.73 m2 for chronic renal failure; BMI formula and obesity threshold of 30 or greater). Medication exposure windows are set (specified drugs must have been taken as prescribed for at least the 30 days before onset or worsening; augmentation requires continuous dopaminergic agent or tramadol exposure for at least three months before worsening).
• “Relevant service” is specifically defined in the Schedule (eligible war service, defence service and peacetime service under MRCA), and the SOP requires that any factor relied upon must be related to that relevant service (s 10(1); Schedule 1 definitions).
• Interaction with other SOPs: where a listed factor refers to another injury or disease covered by a separate SOP, that other SOP’s factors apply as in force (s 11).

The instrument frames RLS and death from RLS as conditions that can be related to relevant service, subject to the claimant establishing at least one of the listed factors and satisfying the requirements of sections 7-11. The RMA’s statement of view in s 8 is an evidentiary prefatory finding but does not eliminate the statutory requirement that a claimant show a listed factor (and that it be related to relevant service).

The SOP affects people making claims under section 120B of the VEA or section 339 of the MRCA for restless legs syndrome or death from restless legs syndrome (s 5). Those statutes (not reproduced here) govern the processes for claiming incapacity, disease or death as service‑related. The instrument is addressed to decision‑makers assessing those claims and to claimants and their advisers, because it identifies the medical findings and factual circumstances that will satisfy the RMA’s evidentiary test.

Specific groups affected include:

• Claimants (veterans, members of the Forces) who assert that their RLS or death from RLS is connected with relevant service. They must prove on the balance of probabilities that at least one of the factors in s 9 existed and was related to the person’s relevant service (s 9; s 10(1)).
• Medical practitioners preparing reports for claimants and decision‑makers. The SOP sets out the clinical diagnostic criteria of RLS (s 7(2)) and objective thresholds (Schedule 1) that reports should address: onset/worsening dates, frequency/duration of symptoms, ferritin, GFR, history of medications and durations, BMI history, smoking pack‑years, pregnancy status, diagnoses of multiple sclerosis, COPD, obstructive sleep apnoea, spinal cord lesions, peripheral neuropathy or radiculopathy, and dialysis records where relevant.
• Administrative decision‑makers within agencies responsible for VEA/MRCA claims. They must apply this SOP as an evidentiary standard when relevant and may need to assess whether a listed factor is causally related to a person’s relevant service (s 5; s 10(1)-(2)).
• Parties and advisers involved in appeals or reviews of decisions under the VEA/MRCA framework will need to consider this SOP in preparing or contesting expert evidence, because the SOP supplies determinative medical nexus factors that govern connection findings on the balance of probabilities.

The Schedule’s definition of “relevant service” narrows the universe of service types that make the SOP applicable: it includes eligible war service other than operational, defence service other than hazardous service and British nuclear test defence service, and peacetime service under the MRCA. Changes to that definition were made by the May 2023 amendment (endnote 3 and 4 refer to the amendment history). The SOP therefore has particular application to claims where the claimant’s service falls within the Schedule’s defined categories.

The instrument is an evidentiary standard; it imposes no administrative duties on private citizens beyond the obligation inherent in making a claim to demonstrate entitlement under the VEA/MRCA framework. It does, however, place specific evidential demands and creates procedural rights in the statutory claim process indirectly by setting out what must be shown to establish service connection.

Key legal effects that operate as duties or rights for parties in the claims process are:

• Right to rely on the SOP as the RMA’s statement of factors which, if established and related to relevant service, are sufficient on the balance of probabilities to connect RLS or death from RLS with service (s 8; s 9). Claimants therefore have the right to frame their medical evidence to engage one or more of these factors.
• Duty on claimants to demonstrate that at least one factor in s 9 existed at the time of clinical onset or clinical worsening, and that the factor was related to their relevant service as defined in Schedule 1 (s 9; s 10(1)). The instrument does not state the types of documentary proof required, but the definition of factors supplies objective biometric thresholds and temporal requirements that the claimant will need to meet.
• Duty to distinguish between “arising out of” service and “suffered or contracted before or during (but did not arise out of)” service. Section 10(2) makes clear that subsections 9(10)-9(22) pertain only to material contribution or aggravation in persons who had RLS before or during relevant service (but where the disease did not arise out of that service). A claimant whose RLS arose out of service will not be able to rely on those aggravation/material contribution provisions in the same manner.
• If a listed factor refers to another injury or disease covered by a separate SOP, then that other SOP applies. Accordingly, claimants and advisers must identify and comply with the terms of relevant SOPs for co‑morbid or causative conditions (s 11).
• The RMA’s prefatorial statement (s 8) of the existence of a probable relationship between RLS and relevant service is not a per se entitlement; the SOP still requires the factual showing described in s 9 and the link to relevant service per s 10. The practical effect is that decision‑makers should treat the SOP as the RMA’s medical consensus and apply it when assessing claims, but claimants must still meet the SOP’s listed criteria.

The instrument does not create judicial rights of appeal, procedural time frames, or administrative steps; those remain governed by the VEA and MRCA. The SOP provides the medical yardstick that governs the nexus question within that broader statutory claims framework.

The SOP is a determinative evidentiary instrument used by decision‑makers assessing VEA/MRCA claims. It does not itself prescribe civil or criminal penalties, nor does it create enforcement mechanisms or sanctions in the way primary legislation or regulatory offences do. There are three direct legal points to note from the text:

• No penalty provisions: the instrument contains no offence provisions, fines, or penal powers. It is an administrative/medical standard (see the instrument’s form and the authority provision s 3).
• Role in administrative enforcement of entitlements: the primary enforcement effect of the SOP is indirect. Decision‑makers will apply the SOP when determining whether a claimant’s RLS or death from RLS is connected with relevant service for the purposes of entitlements under the VEA or MRCA. The SOP therefore governs the factual threshold for finding service connection and so controls whether entitlements are granted, denied, or limited. The SOP does not itself award or deny benefits; it is used by the relevant decision‑making body under the VEA/MRCA.
• Appeal and review pathways are not set out in this instrument. The SOP does not change the statutory appeal and review rights found in the VEA/MRCA regimes; those procedural and review mechanisms remain the route for challenging a claim decision in which the SOP has been applied.

For practitioners and advisers, enforcement risk therefore lies in the administrative consequences of failing to establish the SOP factors in evidence: a claim may be refused if no listed factor is established as related to relevant service. The instrument’s amendment history and prescribed definitions (for example precise lab thresholds) mean that evidentiary proof must be consistent with the Schedule’s technical specifications to avoid administrative denial. The SOP does not authorise penal measures against incorrect medical opinion, nor does it purport to regulate medical practice; it specifies the medical facts that, if established, create a legally sufficient connection to service for claim purposes.

This instrument is expressly made under subsection 196B(3) of the Veterans' Entitlements Act 1986 (s 3). It applies to claims to which section 120B of the VEA or section 339 of the MRCA applies (s 5). Therefore its primary legal interoperability is with those two Acts. The instrument interacts with other legal and administrative instruments in several concrete ways:

• VEA and MRCA claim frameworks: the SOP functions within the VEA/MRCA decision‑making processes. It does not replace or alter the substantive entitlements in those Acts; rather, it determines which medical and factual circumstances provide a sufficient nexus to service. The instrument does not itself alter procedural or appeal rules which remain in the VEA/MRCA.
• Other Statements of Principles: section 11 provides a cross‑instrument interaction rule. If a factor in s 9 refers to an injury or disease that is the subject of another SOP determined under subsection 196B(3) of the VEA, then the factors in that other SOP apply in accordance with its terms as in force from time to time. This creates layered dependency across SOPs and requires claimants and decision‑makers to consult multiple SOPs when co‑morbid or causative conditions are present.
• ICD coding: section 7(3)-(4) refers to ICD‑10‑AM code G25.81 but clarifies that for the purposes of applying the SOP, the meaning is that given in subsection 7(2). The instrument therefore uses the ICD code as an identifier but makes the statutory clinical definition determinative.
• Definitions and technical thresholds: the Schedule provides precise biomedical definitions (for example chronic renal failure, iron deficiency, BMI calculations) which may interact with other regulatory or medical standards, clinical guidelines, or diagnostic criteria outside the SOP. Decision‑makers will apply the Schedule definitions when assessing evidence of those clinical conditions within the SOP’s context.
• Amendment and legislative process: the endnotes record that the SOP was made on 25 October 2022 and commenced on 21 November 2022, and was amended by No. 61 of 2023 with effect 30 May 2023. Endnote 4 notes that Schedule 1’s relevant service definition was amended by No. 61 of 2023. The instrument references the Legislation Act and the conventions used in compilation and endnotes, which governs how amendments, misdescribed amendments and compilation notes are to be interpreted.
• Non‑criminal administrative consequences: because the SOP operates as an evidentiary standard in claims, it influences administrative outcomes, but does not itself create civil liabilities or criminal sanctions. Appeal and review rights under VEA/MRCA continue to apply where administrative outcomes based on the SOP are contested.

Practically, claims involving co‑morbid conditions will require simultaneous engagement with the SOP for RLS and any other applicable SOPs. The Schedule’s definitions and the specific temporal/threshold requirements mean that evidence prepared for other legal processes may need to be tailored to match the SOP’s specifications to be accepted in VEA/MRCA decisions.

The compilation and endnotes included in the text record the instrument’s legislative history and amendments. The key dates and amendments recorded in the instrument are:

• Original SOP: registered 25 October 2022 (F2022L01399) and commenced 21 November 2022, as shown in Endnote 3.
• Amendment: Amendment Statement of Principles concerning restless legs syndrome (No. 61 of 2023), registered 18 May 2023 (F2023L00558), with a commencement date of 30 May 2023 (Endnote 3). The compilation note indicates the day of commencement of the amendment was 30 May 2023.
• Endnote 4 (Amendment history) reports specific amendments at the provision level. It records that:
  • Section 2 was repealed and substituted in accordance with the Legislation Act s 48D style change (notation shows “rep LA s 48D”).
  • Section 4 was repealed and substituted in accordance with the Legislation Act s 48C style change (“rep LA s 48C”).
  • Schedule 1 , Dictionary , relevant service was amended by No. 61 of 2023.

The compilation text warns that uncommenced amendments (if any) are not shown and that modifications by other laws may not be reflected in the compiled text; it points readers to the Legislation Register for current details. The endnotes include standard Legislation Act editorial commentary on misdescribed amendments and compilation conventions.

Operationally, the May 2023 amendment altered the Schedule’s definition of relevant service. Because “relevant service” is a gating definition for whether a SOP can apply and for how factors are to be related to service (s 10(1)), any amendment to that definition has a direct practical effect on the class of service where the SOP can be deployed in claim assessments. The compilation does not reproduce an explanatory memorandum or ministerial second reading speech for the amendment, so the textual amendment must be read directly in the amending instrument to identify the precise wording changes beyond the summary in the endnotes.

Practitioners should note that the RMA periodically revises SOPs as medical evidence evolves; the endnotes and the Legislation Register are the authoritative sources to track current and prospective amendments. The SOP itself contains cross‑references indicating that when other SOPs change, their updated terms will affect factors that refer to them (s 11).

The instrument itself does not record any judicial or tribunal decisions concerning this particular SOP. There are no cases or litigation references within the compiled text. The endnotes provide legislative history and procedural information about amendments and compilation practice but do not list any appeals or challenges to this SOP.

Because this SOP is an administrative evidentiary instrument applied within the VEA and MRCA claim systems, litigation or administrative review could arise where claimants contest a decision that applied this SOP. Any such litigation or merits review would occur under the appeal and review mechanisms of the VEA or MRCA or in the relevant courts or tribunals, but the instrument does not include or annotate any such litigation history.

Practitioners seeking precedential guidance on the application of this SOP will therefore need to search administrative tribunal and court decisions externally to identify how decision‑makers and reviewers have applied the specific factors, handled conflicts between competing expert opinions on onset/worsening, and interpreted Schedule thresholds. The compiled instrument itself includes no summaries of judicial interpretations or examples of how the listed factors have been treated in contested cases.

In short, within this text there is no litigation history to report. That absence should be treated as a gap in this document rather than as evidence that no disputes have occurred in practice. To find case law or tribunal decisions applying this SOP, a practitioner will need to consult administrative tribunal databases, court registries and VEA/MRCA decision records.

This SOP contains a number of technical and procedural features that commonly cause problems in claim preparation and decision‑making. The following are concrete, source‑grounded pitfalls that advisers and claimants should watch for.

• Strict clinical criteria for RLS: s 7(2) prescribes four core symptoms plus objective frequency and duration thresholds (at least three times per week for at least three consecutive months) and a requirement for significant distress or impairment. Medical evidence that documents only episodic symptoms, or symptoms for shorter durations, will not meet the SOP’s definition even if an ICD code is present. The instrument emphasises that the ICD code is not determinative (s 7(3)-(4)).
• Objective laboratory/physiological thresholds: several factors require precise lab or clinical thresholds in Schedule 1. For example, iron deficiency is defined as serum ferritin <30 micrograms per litre; chronic renal failure requires GFR <15 mL/min/1.73 m2 for at least 3 months or chronic dialysis; obesity is BMI ≥30 calculated as W/H2. Evidence that does not provide these precise numbers or contemporaneous measurements risks being insufficient to trigger the relevant factor.
• Temporal qualification and exposure windows: many factors require temporal specificity. Specified drugs must have been taken for at least 30 days before onset or worsening (s 9(5), s 9(14)); augmentation requires continuous dopaminergic agent or tramadol use for at least three months before worsening (s 9(21)); smoking must be at least 10 pack‑years and cessation within 5 years if smoking ceased before onset or worsening (s 9(7), s 9(16)); obesity must have persisted for at least 5 years prior to onset or worsening (s 9(8), s 9(17)). Failure to document timing precisely will defeat reliance on the factor.
• Relationship to relevant service: s 10(1) requires factors to be related to the person’s relevant service as defined in the Schedule. The Schedule’s definition of relevant service is narrower than all possible service types; it excludes certain operational or hazardous categories as referenced. The May 2023 amendment modified the relevant service definition (endnote 4). Claimants must therefore align demonstrated exposures or conditions with the type of service that the Schedule recognises.
• Distinction between causation and aggravation: s 10(2) makes a sharp legal distinction. Subsections 9(10)-9(22) apply only to material contribution to or aggravation of RLS where the disease was suffered or contracted before or during (but did not arise out of) relevant service. If a claimant alleges RLS arose out of service, they cannot rely on those aggravation provisions in the same way. Practically, claimants need to prove whether the disease arose out of service or pre‑existed service; a misclassification changes which factors can be relied on.
• Cross‑referenced SOPs: s 11 provides that when a factor in s 9 refers to another injury or disease that itself is governed by another SOP, the other SOP’s factors apply. This can produce layered evidential requirements and the need to comply with multiple SOP definitions and thresholds.
• Vague factor: “inability to obtain appropriate clinical management” (s 9(22)) is open to interpretation. The SOP lists this as a factor, but does not define what evidence will suffice to establish inability to obtain management. Absent further administrative guidance or jurisprudence, claimants should preserve contemporaneous evidence of attempts to access care, waitlist dates, referrals and correspondence.
• Medication lists and clinical naming: the specified list of drugs in Schedule 1 includes classes and examples (antipsychotics such as olanzapine, quetiapine; SSRIs such as citalopram, escitalopram, fluoxetine, sertraline; SNRIs including venlafaxine; and others). Claims relying on medication exposure must tie prescription records to the list and show the required exposure window and that use was “as prescribed for ongoing use” (s 9(5), s 9(14)).
• Epidemiological disclaimers versus individual claims: s 8 is an RMA-level view that, on available medical‑scientific evidence, it is more probable than not that RLS can be related to relevant service. That statement is an evidential baseline and does not replace the requirement that a claimant satisfies the specific factors and their relation to service in any individual case.

These features are concrete, derivable from the instrument’s text. The practical consequence is that claim preparation must be meticulous about dates, objective test results, medication history, and the relationship between exposures and service type. Missing a lab value, an exact date, a medication duration or a BMI history is not a mere technicality; the SOP has been drafted so that those particulars determine whether a factor is present.

For claimants, treating practitioners and advisers, compliance means assembling evidence that matches the SOP’s precise clinical criteria, temporal windows and Schedule definitions. The following checklist maps the SOP’s factors and definitions (s 7-11, Schedule 1) to practical evidentiary steps. The SOP itself does not prescribe documentary forms; these steps are derived from the instrument’s technical requirements.

Core diagnostic evidence for RLS (s 7(2)):

• Obtain a medical report that explicitly addresses the four core clinical features set out in s 7(2)(a)(i)-(iv), including frequency and duration (at least three times per week for at least three consecutive months) and evidence of significant distress or functional impairment (s 7(2)(b)(i)-(ii)).
• Ensure the report excludes conditions listed in the instrument’s note (myalgia, venous stasis, leg oedema, arthritis, leg cramps, habitual foot tapping) or explains why those conditions do not solely account for the symptoms (s 7(2)(b)(iii)).

Proof of factors in section 9:

• Diabetes mellitus (s 9(1), s 9(10)): provide contemporaneous diabetic diagnosis, HbA1c records and dates showing diabetes was present at onset/worsening.
• Iron deficiency (s 9(2), s 9(11)): supply serum ferritin measurements showing <30 micrograms/L at the time of onset or worsening (Schedule 1).
• Chronic renal failure (s 9(3), s 9(12)): supply GFR or equivalent records showing GFR <15 mL/min/1.73 m2 for at least 3 months, or records of renal replacement therapy/dialysis (Schedule 1).
• Neurological disorders listed (s 9(4), s 9(13)): provide imaging, neurology reports, EMG/NCS or other diagnostics showing spinal cord lesion, peripheral neuropathy or radiculopathy as defined in Schedule 1, with dates.
• Specified drugs (s 9(5), s 9(14)): provide prescription records showing use “as prescribed for ongoing use” and continuous exposure for at least 30 days before onset or worsening. Align drug names to the specified list in Schedule 1.
• Multiple sclerosis (s 9(6), s 9(15)): neurology records confirming diagnosis with relevant dates.
• Smoking history (s 9(7), s 9(16)): construct pack‑year calculations as defined in Schedule 1, with dates and a calculation that confirms at least 10 pack-years and cessation timing if applicable.
• Obesity (s 9(8), s 9(17)): provide weight and height records over time to calculate BMI using the Schedule formula (W/H2), showing BMI ≥30 for at least 5 years before onset/worsening.
• Pregnancy (s 9(9), s 9(18)): obstetric notes recording pregnancy at time of onset/worsening.
• COPD and obstructive sleep apnoea (s 9(19)-(20)): respiratory/sleep clinic diagnoses with dates.
• Augmentation due to dopaminergic agents or tramadol (s 9(21)): supply prescription and dispensing records showing continuous exposure to levodopa, pramipexole or tramadol for at least three months prior to worsening, and specialist notes that document augmentation if claimed.
• Inability to obtain appropriate clinical management (s 9(22)): compile contemporaneous evidence of attempts to obtain care, referrals, waiting list documentation, correspondence, or other material showing lack of access. The SOP does not define the required proof, so contemporaneous administrative records and practitioner statements will be important.

Service nexus and relevant service (s 10; Schedule 1):

• Establish the type of relevant service the claimant rendered and ensure it falls within the Schedule’s definition (eligible war service other than operational service, defence service other than hazardous service and British nuclear test defence service, or peacetime service under MRCA). The May 2023 amendment altered the relevant service definition; confirm the operative text for the claim period.
• Correlate the factor relied upon with service records: e.g., medication prescribed in service, documented pregnancy during service, documented exposure in service that led to a neurological injury, service medical records showing diabetes or renal failure during service. Because s 10(1) requires the factor to be related to the relevant service, evidence from service medical records, treatment logs and contemporaneous reporting is often decisive.

Interaction with other SOPs (s 11):

• If a factor refers to another condition covered by an SOP, obtain evidence that meets that other SOP’s requirements. Cross‑reference the other SOP to ensure compliance with its definitions and thresholds.

Practical documentation tips:

• Provide dated, signed medical reports that address the SOP elements in clear sequence: diagnosis of RLS under s 7(2), presence of the particular s 9 factor with required thresholds and timing, and an opinion on whether the factor is related to the claimant’s relevant service.
• Where lab thresholds are required, include the raw lab values and dates. Summary statements are insufficient without the underlying numbers.
• For medication exposure, provide both prescribing documents and dispensing records where available to demonstrate continuous exposure and dosage if that is relevant to augmentation.
• For BMI and pack‑year calculations, include the calculations and source data (dates and measurements, smoking amounts per day over time).
• If relying on “inability to obtain appropriate clinical management”, gather documentary evidence that shows attempts to obtain care, such as referrals, appointment letters and communications with health services.

Timing and review:

• Confirm the operative SOP text and any amendments that were in force at the relevant time of decision. The compilation notes the original registration and the May 2023 amendment. Use the Legislation Register to verify the current text.
• Prepare for layered evidentiary requirements where more than one SOP applies; cross‑check other SOPs that may be implicated by the listed factors.

In sum, compliance requires matching factual proof to the SOP’s technical language. The Schedule supplies deterministic thresholds; the SOP supplies temporal windows and relational rules. Evidence that is general, undated or fails to supply the specific values and timings in the Schedule will risk being treated as insufficient to satisfy the SOP on the balance of probabilities. Practitioners should assemble a single, coherent medical narrative that explictly addresses each legal element the SOP requires.